600511 Stock Overview
Distributes pharmaceutical products in China. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 1/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 5/6 |
China National Medicines Corporation Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥35.00 |
| 52 Week High | CN¥38.00 |
| 52 Week Low | CN¥27.12 |
| Beta | 0.50 |
| 11 Month Change | 10.65% |
| 3 Month Change | 12.61% |
| 1 Year Change | 18.36% |
| 33 Year Change | 15.09% |
| 5 Year Change | 43.27% |
| Change since IPO | 990.91% |
Recent News & Updates
We Think China National Medicines (SHSE:600511) Can Manage Its Debt With Ease
Nov 12
The China National Medicines Corporation Ltd. (SHSE:600511) Third-Quarter Results Are Out And Analysts Have Published New Forecasts
Oct 25China National Medicines Corporation Ltd.'s (SHSE:600511) Prospects Need A Boost To Lift Shares
Sep 26Recent updates
We Think China National Medicines (SHSE:600511) Can Manage Its Debt With Ease
Nov 12The China National Medicines Corporation Ltd. (SHSE:600511) Third-Quarter Results Are Out And Analysts Have Published New Forecasts
Oct 25China National Medicines Corporation Ltd.'s (SHSE:600511) Prospects Need A Boost To Lift Shares
Sep 26Calculating The Fair Value Of China National Medicines Corporation Ltd. (SHSE:600511)
Sep 10Returns On Capital At China National Medicines (SHSE:600511) Paint A Concerning Picture
Jul 28China National Medicines Corporation Ltd.'s (SHSE:600511) Low P/E No Reason For Excitement
Jun 24China National Medicines (SHSE:600511) Has Announced That It Will Be Increasing Its Dividend To CN¥0.854
Jun 07Is China National Medicines (SHSE:600511) Using Too Much Debt?
Jun 05Calculating The Fair Value Of China National Medicines Corporation Ltd. (SHSE:600511)
May 21Capital Allocation Trends At China National Medicines (SHSE:600511) Aren't Ideal
Apr 10China National Medicines (SHSE:600511) Could Easily Take On More Debt
Feb 28Shareholder Returns
| 600511 | CN Healthcare | CN Market | |
|---|---|---|---|
| 7D | 2.2% | -2.0% | -2.1% |
| 1Y | 18.4% | -17.0% | 2.8% |
Return vs Industry: 600511 exceeded the CN Healthcare industry which returned -17% over the past year.
Return vs Market: 600511 exceeded the CN Market which returned 2.8% over the past year.
Price Volatility
| 600511 volatility | |
|---|---|
| 600511 Average Weekly Movement | 5.7% |
| Healthcare Industry Average Movement | 8.7% |
| Market Average Movement | 8.4% |
| 10% most volatile stocks in CN Market | 12.7% |
| 10% least volatile stocks in CN Market | 5.7% |
Stable Share Price: 600511 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 600511's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 3,138 | Guotao Tian | www.cncm.com.cn |
China National Medicines Corporation Ltd., together with its subsidiaries, distributes pharmaceutical products in China. The company also manufactures and sells new drugs and finished drugs; sells Chinese patent medicines and western medicines, and medical equipment; and offers warehousing and import and export agency services. It serves hospitals, retail pharmacies, and medical institutions.
China National Medicines Corporation Ltd. Fundamentals Summary
| 600511 fundamental statistics | |
|---|---|
| Market cap | CN¥26.41b |
| Earnings (TTM) | CN¥2.16b |
| Revenue (TTM) | CN¥51.19b |
12.2x
P/E Ratio0.5x
P/S RatioIs 600511 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 600511 income statement (TTM) | |
|---|---|
| Revenue | CN¥51.19b |
| Cost of Revenue | CN¥47.36b |
| Gross Profit | CN¥3.83b |
| Other Expenses | CN¥1.67b |
| Earnings | CN¥2.16b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Nov 27, 2024
| Earnings per share (EPS) | 2.87 |
| Gross Margin | 7.49% |
| Net Profit Margin | 4.23% |
| Debt/Equity Ratio | 1.5% |
How did 600511 perform over the long term?
See historical performance and comparison